

VPA10996/264/001

Porcilis M Hyo ID ONCE emulsion for injection for pigs

Variation	Summary	Date
Vet - F.II.a.3 b) 2.	VRA-S - Vet - F.II.a.3 b) 2. - b) Other excipients 2. Change that relates to a biological/immunological product - F.II.a.3 b) 2. Quality Changes - Finished Product - Description and composition - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product	12/02/24
Vet - F.II.e.2 z)	VRA-S - Vet - F.II.e.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.2 z) Quality Changes - Container closure system - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	24/10/23
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy, Pharmacovigilance changes - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	03/10/23
Vet - F.II.d.2 z)	VRA-R - Vet - F.II.d.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.2 z) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	02/10/23
Vet - F.I.b.2 z)	VRA-R - Vet - F.I.b.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.b.2 z) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	02/10/23
Vet - F.I.a.2 b)	VRA-S - Vet - F.I.a.2 b) - b) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - F.I.a.2 b)	02/10/23

	Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	
Vet - F.I.a.3 b)	VRA-R - Vet - F.I.a.3 b) - b) The scale for a biological/immunological active substance is increased/decreased without process change (e.g. duplication of line) - F.I.a.3 b) Quality Changes - Active Substance - Manufacture -Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - The scale for a biological/immunological active substance is increased/decreased without process change (e.g. duplication of line)	02/10/23
Vet - F.I.a.1 d)	VRA-S - Vet - F.I.a.1 d) - d) The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - F.I.a.1 d) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product	02/10/23
Vet - G.I.4	VRA-S - Vet - G.I.4 - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data. - G.I.4 Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data.	19/12/22
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with	15/12/22

	Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	
--	---	--